EGFR, KRAS, BRAF and ALK gene alterations in lung adenocarcinomas: patient outcome, interplay with morphology and immunophenotype Source: Eur Respir J 2014; 43: 872-883 Year: 2014
Residential radon, EGFR mutations and ALK alterations in never-smoking lung cancer cases Source: Eur Respir J 2016; 48: 1462-1470 Year: 2016
Germ-line exon 21 EGFR mutations, V843I and P848L, in nonsmall cell lung cancer patients Source: Eur Respir Rev 2014; 23: 390-392 Year: 2014
KRAS & TP53 mutations cause malignant mesothelioma Source: ERS Lung Science Conference 2017 Year: 2017
Prognostic value of TP53, KRAS and EGFR mutations in nonsmall cell lung cancer: the EUELC cohort Source: Eur Respir J 2012; 40: 177-184 Year: 2012
K-RAS oncogenic mutations in patients with nonsmall cell lung cancer Source: Annual Congress 2007 - Biology of thoracic malignancies Year: 2007
LSC - 2017 - KRAS & TP53 mutations cause malignant mesothelioma Source: International Congress 2017 – Pleural disease and mesothelioma: from the bench to the bedside Year: 2017
Survival outcomes of patients diagnosed with lung adenocarcinoma with ALK gene rearrangement Source: Virtual Congress 2021 – Therapy of lung cancer Year: 2021
RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer Source: Eur Respir J 2012; 39: 677-684 Year: 2012
FGFR1 gene aberrations and FGFR1 protein expression in squamous non-small cell lung cancer (Sq-NSCLC). Source: Virtual Congress 2021 – Biology of lung cancer: preclinical and translational research Year: 2021
Croatian Caucasians with lung adenocarcinoma harbouring EGFR mutations with and without brain metastasis Source: International Congress 2017 – Lung cancer: clinically relevant aspects of epidemiology, co-morbidities, metastasised disease and follow-up Year: 2017
The diagnostic puzzle of ALK rearrangement in lung cancer. A novel intron related abnormality Source: Annual Congress 2013 –Biology and molecular pathology of lung cancer Year: 2013
Cytological samples for the study of EGFR, KRAS and ALK mutations in non-small cell lung cancer Source: Annual Congress 2013 –Progress in bronchoscopy and pathology techniques for diagnosis of thoracic malignancies Year: 2013
p53 gene mutations in lung cancer in Korean Source: Eur Respir J 2005; 26: Suppl. 49, 327s Year: 2005
Aberrant methylation of p16 tumour suppresor gene and DAP kinase in nonsmall cell lung carcinomas Source: Eur Respir J 2001; 18: Suppl. 33, 233s Year: 2001
Arg72Pro P53 gene polymorphism is associated with P53 mutations in non-small cell lung cancer (NSCLC) patients Source: Eur Respir J 2004; 24: Suppl. 48, 78s Year: 2004
Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation Source: Eur Respir J 2011; 37: 624-631 Year: 2011
Evaluation of EGFR mutations and ERCC2 polymorphisms in treatment of non-small cell lung cancer Source: Annual Congress 2005 - Chemotherapy and palliative care Year: 2005
French multicentric validation of ALK rearrangement diagnostic in 547 lung adenocarcinomas Source: Eur Respir J 2015; 46: 207-218 Year: 2015
Concordance of p53 and K-ras mutations in induced sputum and corresponding biopsies of patients with nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 18s Year: 2001